News
10-01-2012, 04:50 AM
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
More... (http://www.news-medical.net/news/20121001/ProStrakan-acquires-US-commercial-rights-to-Fareston-for-treatment-of-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20121001/ProStrakan-acquires-US-commercial-rights-to-Fareston-for-treatment-of-metastatic-breast-cancer.aspx)